Virginie Ory1, William B Kietzman2, Jacob Boeckelman2, Bhaskar V Kallakury3,4, Anton Wellstein2,4, Priscilla A Furth2,5,4, Anna T Riegel2,4. 1. Department of Oncology, Georgetown University, Washington, DC, USA. vo24@georgetown.edu. 2. Department of Oncology, Georgetown University, Washington, DC, USA. 3. Department of Pathology, Georgetown University, Washington, DC, USA. 4. The Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. 5. Department of Medicine, Georgetown University, Washington, DC, USA.
Abstract
PURPOSE: Ductal carcinoma in situ (DCIS) is a pre-invasive lesion of the breast considered a precursor of invasive ductal carcinoma. This study aimed to determine whether activated PPARγ acts as a tumor suppressor in human DCIS progression. METHODS: We utilized the high-affinity PPARγ agonist, efatutazone, to activate endogenous PPARγ in a well-defined model for the progression of basal (triple negative) DCIS, MCFDCIS cells, cultured under 2D and 3D conditions. We studied the effects of activated PPARγ on DCIS progression in MCFDCIS xenograft and C3(1)/Tag transgenic mice treated with 30 mg/kg of efatutazone. RESULTS: In vitro, efatutazone did not alter the MCFDCIS cell proliferation but induced phenotypic and gene expression changes, indicating that activated PPARγ is able to differentiate MCFDCIS cells into more luminal and lactational-like cells. In addition, MCFDCIS tumorsphere formation in 3D was reduced by PPARγ activation. In vivo, efatutazone-treated MCFDCIS tumors exhibited fat deposition along with upregulation of PPARγ responsive genes in both epithelial and stromal compartments, suggesting features of milk-producing mammary epithelial cell differentiation. The efatutazone-treated lesions were less invasive with fewer CD44+/p63+ basal progenitor cells. PPARγ activation downregulated Akt phosphorylation in these tumors, although the ERK pathway remained unchanged. Similar trends in gene expression changes consistent with lactational and luminal cell differentiation were observed in the C3(1)/Tag mouse model after efatutazone treatment. CONCLUSIONS: Our data suggest that activation of the PPARγ pathway differentiates DCIS lesions and may be a useful approach to delay DCIS progression.
PURPOSE:Ductal carcinoma in situ (DCIS) is a pre-invasive lesion of the breast considered a precursor of invasive ductal carcinoma. This study aimed to determine whether activated PPARγ acts as a tumor suppressor in human DCIS progression. METHODS: We utilized the high-affinity PPARγ agonist, efatutazone, to activate endogenous PPARγ in a well-defined model for the progression of basal (triple negative) DCIS, MCFDCIS cells, cultured under 2D and 3D conditions. We studied the effects of activated PPARγ on DCIS progression in MCFDCIS xenograft and C3(1)/Tagtransgenic mice treated with 30 mg/kg of efatutazone. RESULTS: In vitro, efatutazone did not alter the MCFDCIS cell proliferation but induced phenotypic and gene expression changes, indicating that activated PPARγ is able to differentiate MCFDCIS cells into more luminal and lactational-like cells. In addition, MCFDCIS tumorsphere formation in 3D was reduced by PPARγ activation. In vivo, efatutazone-treated MCFDCIS tumors exhibited fat deposition along with upregulation of PPARγ responsive genes in both epithelial and stromal compartments, suggesting features of milk-producing mammary epithelial cell differentiation. The efatutazone-treated lesions were less invasive with fewer CD44+/p63+ basal progenitor cells. PPARγ activation downregulated Akt phosphorylation in these tumors, although the ERK pathway remained unchanged. Similar trends in gene expression changes consistent with lactational and luminal cell differentiation were observed in the C3(1)/Tagmouse model after efatutazone treatment. CONCLUSIONS: Our data suggest that activation of the PPARγ pathway differentiates DCIS lesions and may be a useful approach to delay DCIS progression.
Authors: Mingyue Li; Tak W Lee; Tony S K Mok; Timothy D Warner; Anthony P C Yim; George G Chen Journal: J Cell Biochem Date: 2005-11-01 Impact factor: 4.429
Authors: V Eusebi; E Feudale; M P Foschini; A Micheli; A Conti; C Riva; S Di Palma; F Rilke Journal: Semin Diagn Pathol Date: 1994-08 Impact factor: 3.464
Authors: Matthew R Smith; Judith Manola; Donald S Kaufman; Daniel George; William K Oh; Elisabetta Mueller; Susan Slovin; Bruce Spiegelman; Eric Small; Philip W Kantoff Journal: Cancer Date: 2004-10-01 Impact factor: 6.860
Authors: William B Kietzman; Garrett T Graham; Virginie Ory; Ghada M Sharif; Max H Kushner; Gregory T Gallanis; Bhaskar Kallakury; Anton Wellstein; Anna T Riegel Journal: Mol Cancer Ther Date: 2019-08-26 Impact factor: 6.261
Authors: Ghada M Sharif; Moray J Campbell; Apsra Nasir; Surojeet Sengupta; Garrett T Graham; Max H Kushner; William B Kietzman; Marcel O Schmidt; Gray W Pearson; Olivier Loudig; Susan Fineberg; Anton Wellstein; Anna T Riegel Journal: Cancer Res Date: 2021-06-16 Impact factor: 12.701